Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EMA seeks to optimize use of accelerated assessment and conditional authorization pathways

This article was originally published in SRA

Executive Summary

The European Medicines Agency has proposed improvements relating to the use of its accelerated assessment and conditional marketing authorization pathways. Both pathways are designed to bring medicines that address unmet medical needs to market faster but have been criticized for failing to fully meet their intended aims1-4.